Boston-based mobile brain rehabilitation company Constant Therapy has raised $2 million in a round led by Golden Seeds with participation from Kapor Capital, Launchpad Venture Group, Pond Capital, and Community Health Network of Connecticut. MobiHealthNews first reported on this round last month, when the company disclosed a $1.96 million raise in the SEC.

This brings the company's total funding to at least $2.7 million. Existing investors include Boston University, TiE Angels Boston, and serial entrepreneur Andy Palmer.

Constant Therapy has developed a mobile app designed to provide therapy to patients who have traumatic brain injury, stroke, aphasia, and learning disabilities.

"Constant Therapy quite literally puts speech, language and cognitive therapy in your pocket," Constant Therapy CEO Keith Cooper said in a statement. "Developed by some of the world's foremost experts in brain rehabilitation, it allows us to harness both data and science to optimize the effectiveness of treatment, customize it for each patient and then deliver it for individual use, or as an integral part of clinician-led therapy."

The offering, which launched in June 2014, uses a feature called the NeuroPerformance Engine to create a personalized profile of each person’s strengths and weaknesses. The app then delivers a combination of exercises to improve their brain function. Constant Therapy’s app offers about 58 science-based task categories and more than 60,000 exercises, according to the company.

Some healthcare organizations that use Constant Therapy include Spaulding Rehabilitation Network, the Stroke Comeback Center, and The MossRehab Aphasia Center.

Patients and caregivers are also able to purchase an app subscription directly for $19.99 per month, $199.99 per year, or $299.99 for three years. If users do not already have a tablet, Constant Therapy said it would provide people who purchased one or three year subscriptions with a seven-inch Android tablet.